We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+13.63%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.92B
AUM Growth
-$350M
(-11%)
Cap. Flow
-$566M
Cap. Flow
% of AUM
-19.43%
Top 10 Holdings %
Top 10 Hldgs %
63.81%
Holding
52
New
7
Increased
11
Reduced
10
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$81.8M |
| 2 |
Tenet Healthcare
THC
|
+$46.2M |
| 3 |
GSK
GSK
|
+$41.6M |
| 4 |
Myriad Genetics
MYGN
|
+$37.3M |
| 5 |
Align Technology
ALGN
|
+$35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$105M |
| 2 |
Charles River Laboratories
CRL
|
+$98.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$67.8M |
| 4 |
Universal Health Services
UHS
|
+$64.9M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$63.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.56% |
| 2 | Consumer Discretionary | 0.54% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZIMV
26
DELISTED
ZimVie
ZIMV
| $24.3M | 0.83% |
2,600,000
| – | – |
|
27
Exelixis
EXEL
$13.2B
| $21.7M | 0.74% |
1,350,000
| – | – |
|
|
NUVA
28
DELISTED
NuVasive, Inc.
NUVA
| $20.6M | 0.71% |
500,000
| – | – |
|
29
OraSure Technologies
OSUR
$275M
| $20.5M | 0.7% |
4,250,000
| – | – |
|
30
Puma Biotechnology
PBYI
$439M
| $17.9M | 0.61% |
4,235,000
| – | – |
|
|
CSII
31
DELISTED
Cardiovascular Systems, Inc.
CSII
| $17.7M | 0.61% |
1,300,000
| – | – |
|
32
Peloton Interactive
PTON
$2.46B
| $15.9M | 0.54% |
2,000,000
-1,000,000
| -33% | -$9.59M |
|
33
Glaukos
GKOS
$10.4B
| $15.3M | 0.52% |
350,000
| – | – |
|
|
NSTG
34
DELISTED
NanoString Technologies, Inc.
NSTG
| $12M | 0.41% |
1,500,000
+500,000
| +50% | +$4.34M |
|
|
BKDT
35
DELISTED
Brookdale Senior Living Inc. 7.00% Tangible Equity Units
BKDT
| $11.1M | 0.38% |
+250,000
| New | +$11.8M |
|
36
Solid Biosciences
SLDB
$849M
| $7.63M | 0.26% |
+1,418,439
| New | +$9.3M |
|
37
Inogen
INGN
$167M
| $6.01M | 0.21% |
305,000
-520,000
| -63% | -$11.2M |
|
|
CANO
38
DELISTED
Cano Health, Inc.
CANO
| $5.48M | 0.19% |
40,000
-10,000
| -20% | -$3.39M |
|
39
Enanta Pharmaceuticals
ENTA
$392M
| $5.12M | 0.18% |
+110,000
| New | +$5.01M |
|
40
Biogen
BIIB
$30.4B
| – | – |
-200,000
| Closed | -$53.4M |
|
|
41
BioMarin Pharmaceuticals
BMRN
$12.2B
| – | – |
-800,000
| Closed | -$67.8M |
|
|
42
Charles River Laboratories
CRL
$12.7B
| – | – |
-500,000
| Closed | -$98.4M |
|
43
Incyte
INCY
$24.3B
| – | – |
-750,000
| Closed | -$50M |
|
44
Medtronic
MDT
$111B
| – | – |
-500,000
| Closed | -$40.4M |
|
45
CALL
Merck
MRK
$314B
| – | – |
-1,500,000
| Closed | -$129M |
|
46
CALL
Pfizer
PFE
$150B
| – | – |
-2,500,000
| Closed | -$109M |
|
47
QuidelOrtho
QDEL
$825M
| – | – |
-600,000
| Closed | -$42.9M |
|
48
CALL
Sanofi
SNY
$105B
| – | – |
-1,000,000
| Closed | -$38M |
|
49
Zymeworks
ZYME
$1.77B
| – | – |
-2,865,000
| Closed | -$17.6M |
|
|
RETA
50
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-500,000
| Closed | -$12.6M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Camber Capital Management held 52 positions worth $2.92B, down 11% from $3.27B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Camber Capital Management withdrew a net $566M in Q4 2022, closing 13 positions and reducing 10 holdings. Its most notable exit was Charles River Laboratories, an estimated $98.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 88% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Camber Capital Management opened a new position in Qiagen worth $37.4M.
- Camber Capital Management's largest Q4 2022 buy was Qiagen: 707,292 shares worth $37.4M.
- Camber Capital Management added most to Walgreens Boots Alliance in Q4 2022, an estimated $81.8M increase.
- Camber Capital Management's biggest Q4 2022 reduction was Viatris, cutting an estimated $105M.
- Camber Capital Management fully exited Charles River Laboratories in Q4 2022, selling an estimated $98.4M.
- Camber Capital Management's ten largest holdings make up 64% of its $2.92B portfolio in Q4 2022.
- Camber Capital Management opened 7 new positions and closed 13 in Q4 2022.
- Camber Capital Management's portfolio value fell 11% quarter-over-quarter to $2.92B.
Based on Camber Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.